An Open-label, 52-Week, Multicenter Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
Phase of Trial: Phase III
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Centanafadine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 22 Feb 2019 Status changed from not yet recruiting to recruiting.
- 14 Jan 2019 Planned End Date changed from 1 Mar 2021 to 1 Jun 2021.
- 14 Jan 2019 Planned primary completion date changed from 1 Mar 2021 to 1 Jun 2021.